Knowing When to Fold 'Em: Amicus Pompe Phase II Solid
Positive preliminary data from a Phase II trial with Amicus Therapeutics Inc.'s drug chaperone in Pompe disease, unveiled at an Australian scientific meeting, tickled the company's share price, but investors must wait until year's end for the complete results.
Meanwhile, the company's lead compound, the chaperone Amigal (migalastat) for Fabry disease subject of a deal retooled this summer by partner GlaxoSmithKline plc will finish a Phase III registration study by the end of the year, too.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter